Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Cytokine Storm
Coronavirus
DOI:
10.14336/ad.2020.0228
Publication Date:
2020-03-13T15:44:15Z
AUTHORS (38)
ABSTRACT
A coronavirus (HCoV-19) has caused the novel disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing cytokine storm may be key to save patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown possess a comprehensive powerful immunomodulatory function. This study aims investigate whether MSC transplantation improves outcome of 7 enrolled pneumonia Beijing YouAn Hospital, China, from Jan 23, 2020 Feb 16, 2020. The clinical outcomes, as well changes inflammatory immune function levels adverse effects were assessed for 14 days after injection. MSCs could cure or significantly improve functional outcomes seven without observed effects. pulmonary symptoms these improved 2 transplantation. Among them, two common one patient recovered discharged 10 treatment. After treatment, peripheral lymphocytes increased, C-reactive protein decreased, overactivated cytokine-secreting CXCR3+CD4+ T cells, CXCR3+CD8+ CXCR3+ NK disappeared 3-6 days. In addition, group CD14+CD11c+CD11b<sup>mid</sup> regulatory DC cell population dramatically increased. Meanwhile, level TNF-α was while IL-10 increased treatment compared placebo control group. Furthermore, gene expression profile showed ACE2<sup>-</sup> TMPRSS2<sup>-</sup> which indicated are free infection. Thus, intravenous safe effective pneumonia, especially critically condition.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (27)
CITATIONS (913)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....